ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
Antibodies and antigen-binding antibody fragments that bind to GPIIb/IIIa and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind GPIIb/IIIa on activated platelets while others do not show a preference for binding GPIIb/IIIa on resting versus activated platelets. Some of these antibodies and antibody fragments do not inhibit the interaction of GPIIb/IIIa with fibrinogen, while some others do. The disclosed antibodies do not induce platelet activation. Some of these antibodies and antigen-binding antibody fragments are useful in targeting therapeutic agents such as clotting factors to platelets while others are useful in reducing platelet aggregation and/or thrombus formation.
1 . An antibody or antigen-binding fragment thereof that specifically binds to Glycoprotein IIb/IIIa (GPIIb/IIIa), wherein the antibody or antigen-binding fragment thereof:
(i) preferentially binds to GPIIb/IIIa on activated platelets compared to resting platelets; and
(ii) does not activate platelets.
2 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof does not inhibit the association of fibrinogen with GPIIb/IIIa.
3 . The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises:
(i) the complementarity determining regions (CDRs) of the heavy chain variable domain (VH) amino acid sequence set forth in SEQ ID NOs. 9, 29, 33, or 37;
(ii) an amino acid sequence that is at least 85% identical to the VH amino acid sequence set forth in SEQ ID NOs. 9, 29, 33, or 37;
(iii) the complementarity determining regions of the light chain variable domain (VL) amino acid sequence set forth in SEQ ID NOs. 11, 31, 35, or 39; or
(iv) an amino acid sequence that is at least 85% identical to the VL amino acid sequence set forth in SEQ ID NOs. 11, 31, 35, or 39.
4 .- 8 . (canceled)
9 . An antibody or antigen-binding fragment thereof that specifically binds to Glycoprotein IIb/IIIa (GPIIb/IIIa), wherein the antibody or antigen-binding fragment thereof:
(i) binds to GPIIb/IIIa on both activated platelets and resting platelets; and
(ii) does not activate platelets.
10 . The antibody or antigen-binding fragment thereof of claim 9 , wherein the antibody or antigen-binding fragment thereof comprises:
(i) the complementarity determining regions of VH amino acid sequence set forth in SEQ ID NOs. 5, 13, 17, 21, 25, 41, 45, or 49;
(ii) a VH amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NOs. 5, 13, 17, 21, 25, 41, 45, or 49;
(iii) the complementarity determining regions of the VL amino acid sequence set forth in SEQ ID NOs. 7, 15, 19, 23, 27, 43, 47, or 51; or
(iv) a VL amino acid sequence that is at least 85% identical to the amino acid sequence set forth in SEQ ID NOs. 7, 15, 19, 23, 27, 43, 47, or 51.
11 .- 22 . (canceled)
23 . An antibody or antigen-binding fragment thereof that specifically binds to Glycoprotein IIb/IIIa (GPIIb/IIIa), wherein the antibody or antigen-binding fragment thereof:
(a) specifically binds to GPIIb/IIIa at the same epitope as an antibody comprising the heavy chain variable domain (VH) and the light chain variable domain (VL) amino acid sequences set forth in:
(i) SEQ ID NOs. 5 and 7;
(ii) SEQ ID NOs. 9 and 11;
(iii) SEQ ID NOs. 13 and 15;
(iv) SEQ ID NOs. 17 and 19;
(v) SEQ ID NOs. 21 and 23;
(vi) SEQ ID NOs. 25 and 27;
(vii) SEQ ID NOs. 29 and 31;
(viii) SEQ ID NOs. 33 and 35;
(ix) SEQ ID NOs. 37 and 39;
(x) SEQ ID NOs. 41 and 43;
(xi) SEQ ID NOs. 45 and 47; or
(xii) SEQ ID NOs. 49 and 51; or
(b) competitively inhibits GPIIb/IIIa binding by an antibody comprising the heavy chain variable domain (VH) and the light chain variable domain (VL) amino acid sequences set forth in:
(i) SEQ ID NOs. 5 and 7;
(ii) SEQ ID NOs. 9 and 11;
(iii) SEQ ID NOs. 13 and 15;
(iv) SEQ ID NOs. 17 and 19;
(v) SEQ ID NOs. 21 and 23;
(vi) SEQ ID NOs. 25 and 27;
(vii) SEQ ID NOs. 29 and 31;
(viii) SEQ ID NOs. 33 and 35;
(ix) SEQ ID NOs. 37 and 39;
(x) SEQ ID NOs. 41 and 43;
(xi) SEQ ID NOs. 45 and 47; or
(xii) SEQ ID NOs. 49 and 51
24 .- 25 . (canceled)
26 . An antibody or antigen-binding fragment thereof that specifically binds to Glycoprotein IIb/IIIa (GPIIb/IIIa), comprising a VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3, wherein
(i) the VH-CDR1 sequence comprises YTFTSYGIS (SEQ ID NO:53), the VH-CDR2 sequence comprises WISAYNGNTNYAQKLQG (SEQ ID NO:54), the VH-CDR3 sequence comprises ARDLEYYDSSGYAYGYFDL (SEQ ID NO:55), the VL-CDR1 sequence comprises RSSQSLLHSNGYNYLD (SEQ ID NO:83), the VL-CDR2 sequence comprises LGSNRAS (SEQ ID NO:84), and the VL-CDR3 sequence comprises MQALRLPRT (SEQ ID NO:85);
(ii) the VH-CDR1 sequence comprises GTFSSYAIS (SEQ ID NO:56), the VH-CDR2 sequence comprises GIIPIFGTANYAQKFQG (SEQ ID NO:57), the VH-CDR3 sequence comprises ARDTGYYGASLYFDY (SEQ ID NO:58), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQRSALPRT (SEQ ID NO:88);
(iii) the VH-CDR1 sequence comprises GTFSSYAIS (SEQ ID NO:56), the VH-CDR2 sequence comprises GIIPIFGTANYAQKFQG (SEQ ID NO:57), the VH-CDR3 sequence comprises ARGPPSAYGDYVWDI (SEQ ID NO:59), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DSSNRAT (SEQ ID NO:89), and the VL-CDR3 sequence comprises QQRSHLPPT (SEQ ID NO:90);
(iv) the VH-CDR1 sequence comprises FTFSDHHMD (SEQ ID NO:60), the VH-CDR2 sequence comprises RTRNKANSYTTEYAASVKG (SEQ ID NO:61), the VH-CDR3 sequence comprises ARGPPYYADLGMGV (SEQ ID NO:62), the VL-CDR1 sequence comprises RASQSVSSNLA (SEQ ID NO:91), the VL-CDR2 sequence comprises GASTRAT (SEQ ID NO:92), and the VL-CDR3 sequence comprises QQFNLYPYT (SEQ ID NO:93);
(v) the VH-CDR1 sequence comprises YTFTSYSMH (SEQ ID NO:63), the VH-CDR2 sequence comprises IINPSGGSTSYAQKFQG (SEQ ID NO:64), the VH-CDR3 sequence comprises ARSYDIGYFDL (SEQ ID NO:65), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASKRAT (SEQ ID NO:94), and the VL-CDR3 sequence comprises QQDSFLPFT (SEQ ID NO:95);
(vi) the VH-CDR1 sequence comprises YTFTSYGIS (SEQ ID NO:53), the VH-CDR2 sequence comprises WISAYNGNTNYAQKLQG (SEQ ID NO:54), the VH-CDR3 sequence comprises ARGRPYDHYFDY (SEQ ID NO:66), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQAYNYPFT (SEQ ID NO:96);
(vii) the VH-CDR1 sequence comprises GSISSSSYYWG (SEQ ID NO:67), the VH-CDR2 sequence comprises SIYYSGSTYYNPSLKS (SEQ ID NO:68), the VH-CDR3 sequence comprises ARDFYSSVYGMDV (SEQ ID NO:69), the VL-CDR1 sequence comprises RASQSISSFLN (SEQ ID NO:97), the VL-CDR2 sequence comprises AASSLQS (SEQ ID NO:98), and the VL-CDR3 sequence comprises QQSYVHPLT (SEQ ID NO:99);
(viii) the VH-CDR1 sequence comprises YTFTSYGIS (SEQ ID NO:53), the VH-CDR2 sequence comprises WISAYNGNTNYAQKLQG (SEQ ID NO:54), the VH-CDR3 sequence comprises ARDGLGSSPWSAFDI (SEQ ID NO:70), the VL-CDR1 sequence comprises RSSQSLLHSNGYNYLD (SEQ ID NO:100), the VL-CDR2 sequence comprises LGSNRAS (SEQ ID NO:101), and the VL-CDR3 sequence comprises MQARRSPLT (SEQ ID NO:102);
(ix) the VH-CDR1 sequence comprises YTFTSYYMH (SEQ ID NO:71), the VH-CDR2 sequence comprises VINPSGGSTSYAQKFQG (SEQ ID NO:72), the VH-CDR3 sequence comprises ARLMSGSSGS (SEQ ID NO:73), the VL-CDR1 sequence comprises RASQSVSSSYLA (SEQ ID NO:103), the VL-CDR2 sequence comprises GASSRAT (SEQ ID NO:104), and the VL-CDR3 sequence comprises QQYGGFPLT (SEQ ID NO:105);
(x) the VH-CDR1 sequence comprises YTFTGYYMH (SEQ ID NO:74), the VH-CDR2 sequence comprises SINPNSGGTNYAQKFQG (SEQ ID NO:75), the VH-CDR3 sequence comprises ARDSSWKHDY (SEQ ID NO:76), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQYSFYPLT (SEQ ID NO:106);
(xi) the VH-CDR1 sequence comprises YSISSGYYWG (SEQ ID NO:77), the VH-CDR2 sequence comprises SIYHSGSTNYNPSLKS (SEQ ID NO:78), the VH-CDR3 sequence comprises ARSPRWRSTYANWFNP (SEQ ID NO:79), the VL-CDR1 sequence comprises RASQGISSWLA (SEQ ID NO:107), the VL-CDR2 sequence comprises GASSLQS (SEQ ID NO:108), and the VL-CDR3 sequence comprises QQAAPFPLT (SEQ ID NO:109); or
(xii) the VH-CDR1 sequence comprises YSISSGYYWA (SEQ ID NO:80), the VH-CDR2 sequence comprises SIYHSGSTYYNPSLKS (SEQ ID NO:81), the VH-CDR3 sequence comprises AREHSSSGQWNV (SEQ ID NO: 82), the VL-CDR1 sequence comprises RASQSVSSYLA (SEQ ID NO:86), the VL-CDR2 sequence comprises DASNRAT (SEQ ID NO:87), and the VL-CDR3 sequence comprises QQRSFYFT (SEQ ID NO:110).
27 .- 32 . (canceled)
33 . The antibody or antigen binding fragment thereof of claim 26 , wherein the antibody or antigen binding fragment thereof is a whole antibody, a Fab, a Fab′, a F(ab)2, an scFv, an sc(Fv)2, or a diabody.
34 . A chimeric molecule comprising (i) the antibody or antigen-binding fragment thereof of claim 26 , and (ii) a heterologous moiety.
35 . The chimeric molecule of claim 34 , wherein the heterologous moiety comprises a clotting factor.
36 .- 42 . (canceled)
43 . The chimeric molecule of claim 34 , further comprising a second heterologous moiety.
44 . The chimeric molecule according to claim 43 , wherein the second heterologous moiety comprises a half-life extending moiety.
45 .- 46 . (canceled)
47 . A chimeric molecule comprising (i) the antibody or antigen-binding fragment thereof of claim 26 , (ii) a recombinant Factor VIIa comprising a heavy chain and a light chain, and (iii) a half-life extending moiety.
48 .- 52 . (canceled)
53 . A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 26 , and a pharmaceutically acceptable carrier.
54 . A method of reducing the frequency or degree of a bleeding episode in a human subject in need thereof, comprising administering to the subject an effective amount of the antibody or antigen-binding fragment thereof of claim 26 .
55 .- 57 . (canceled)
58 . A method of treating a blood coagulation disorder in a human subject in need thereof, comprising administering to the subject an effective amount of the antibody or antigen-binding fragment thereof of claim 26 .
59 .- 60 . (canceled)
61 . A method of detecting platelets, comprising:
contacting a human blood preparation with the antibody or antigen-binding fragment thereof of claim 26 ; and
detecting cells in the blood preparation to which the antibody or antigen-binding fragment thereof binds.
62 . A method for enriching platelets, comprising:
contacting a human blood preparation with the antibody or antigen-binding fragment thereof of claim 26 ; and
enriching cells to which the antibody or antigen-binding fragment thereof are bound as compared to those cells in the blood preparation that are not bound by the antibody or antigen-binding fragment thereof.
63 . An isolated nucleic acid comprising a nucleotide sequence that is at least 80% identical to a nucleotide sequence selected from the group consisting of SEQ ID NOs: 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.
64 .- 67 . (canceled)
68 . A recombinant vector comprising the nucleic acid of claim 63 .
69 . A host cell comprising the recombinant vector of claim 68 .
70 .- 72 . (canceled)